Novartis AGNVSNYSE
Loading
Operating Expenses Over TimeStable
Percentile Rank43
3Y CAGR+0.2%
5Y CAGR-0.5%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+0.2%/yr
vs +0.8%/yr prior
5Y CAGR
-0.5%/yr
Consistent
Acceleration
-0.6pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
2 yr
Consecutive declineStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $24.05B | -1.2% |
| 2024 | $24.35B | -0.3% |
| 2023 | $24.42B | +2.0% |
| 2022 | $23.93B | +7.9% |
| 2021 | $22.18B | -9.9% |
| 2020 | $24.63B | -2.1% |
| 2019 | $25.17B | +8.5% |
| 2018 | $23.19B | +10.0% |
| 2017 | $21.07B | -10.9% |
| 2016 | $23.65B | - |